The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. If prostate cancer recurs following initial … Continue reading "FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer"
The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men … Continue reading "Xtandi® Improves Survival in Advanced Prostate Cancer"